OBJECTIVE: Dabigatran is a nov-el target specific oral anticoagulant for stroke prevention in
non valvular atrial fibrillation. Little is still known about its real-world effectiveness and safety …

The study objective was to evaluate the safety and effectiveness of dabigatran and other
direct oral anticoagulants (DOACs) compared with warfarin among patients with nonvalvular …

Background and Purpose—In randomized trials, patients with atrial fibrillation (AF) receiving
dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than …

Background Dabigatran is one of the three newer oral anticoagulants (OACs) recently
approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) …

Background Although dabigatran is 1 of the preferred agents for stroke prevention in atrial
fibrillation, warfarin remains the mainstay treatment in many publicly financed health care …

Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in
clinical practice, increasing in prevalence with age. AF is often associated with structural …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …

Aims We compared the 1‐year safety and effectiveness of dabigatran 110 mg (D110) or 150
mg (D150) twice daily to vitamin K antagonists (VKA) in patients with nonvalvular atrial …

Background and Purpose—Whether dabigatran is associated with different risks of
cardiovascular, bleeding events, and mortality from warfarin in Asian patients with …

Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the
most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKA s) have been the …